X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1902) 1902
Publication (87) 87
Book Review (14) 14
Book Chapter (9) 9
Dissertation (4) 4
Conference Proceeding (2) 2
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1068) 1068
bezafibrate (1004) 1004
male (834) 834
female (578) 578
middle aged (507) 507
bezafibrate - therapeutic use (499) 499
bezafibrate - pharmacology (491) 491
animals (440) 440
index medicus (377) 377
hypolipidemic agents - therapeutic use (363) 363
adult (340) 340
aged (318) 318
triglycerides - blood (269) 269
hypolipidemic agents - pharmacology (247) 247
rats (239) 239
cholesterol - blood (202) 202
pharmacology & pharmacy (200) 200
cholesterol (186) 186
biochemistry & molecular biology (159) 159
mice (159) 159
bezafibrate - administration & dosage (152) 152
hyperlipidemias - drug therapy (152) 152
fenofibrate (146) 146
cholesterol, hdl - blood (143) 143
metabolism (141) 141
lipids - blood (136) 136
bezafibrate - adverse effects (134) 134
cardiac & cardiovascular systems (132) 132
gemfibrozil (131) 131
liver - drug effects (129) 129
risk factors (122) 122
liver - metabolism (120) 120
clofibric acid - analogs & derivatives (118) 118
treatment outcome (117) 117
medicine, general & internal (116) 116
peripheral vascular disease (108) 108
endocrinology & metabolism (106) 106
lipids (106) 106
cells, cultured (101) 101
cholesterol, ldl - blood (100) 100
drug therapy, combination (99) 99
atherosclerosis (97) 97
hypolipidemic agents - adverse effects (96) 96
hypertriglyceridemia (94) 94
double-blind method (92) 92
lipoproteins - blood (92) 92
time factors (92) 92
liver (89) 89
fibrates (85) 85
simvastatin (85) 85
triglycerides (85) 85
expression (83) 83
hypolipidemic agents - administration & dosage (83) 83
fibric acids (82) 82
hypertriglyceridemia - drug therapy (82) 82
gastroenterology & hepatology (81) 81
hypercholesterolemia - drug therapy (79) 79
therapy (76) 76
hypercholesterolemia (75) 75
clofibrate (74) 74
lipoproteins (74) 74
myocardial-infarction (74) 74
hyperlipidemia (73) 73
hyperlipidemias - blood (72) 72
ursodeoxycholic acid (72) 72
clofibric acid - therapeutic use (71) 71
hyperlipoproteinemia type ii - drug therapy (69) 69
fenofibrate - pharmacology (68) 68
clofibric acid - pharmacology (66) 66
ppar-alpha (66) 66
gemfibrozil - pharmacology (65) 65
medicine, research & experimental (65) 65
clofibrate - pharmacology (64) 64
dose-response relationship, drug (64) 64
secondary prevention (64) 64
fenofibrate - therapeutic use (63) 63
follow-up studies (63) 63
rats, wistar (63) 63
risk (62) 62
insulin-resistance (61) 61
clofibrate - analogs & derivatives (60) 60
disease (60) 60
insulin resistance (60) 60
coronary-heart-disease (59) 59
drugs (59) 59
lipoproteins, ldl - blood (59) 59
medicine & public health (59) 59
research (59) 59
analysis (58) 58
rats, sprague-dawley (58) 58
coronary heart-disease (57) 57
kinetics (57) 57
gemfibrozil - therapeutic use (56) 56
gene-expression (56) 56
anticholesteremic agents - therapeutic use (55) 55
pharmaceuticals (55) 55
rna, messenger - metabolism (55) 55
clinical trials as topic (54) 54
fatty acids - metabolism (54) 54
fibrinogen (54) 54
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1707) 1707
German (64) 64
Japanese (41) 41
Spanish (18) 18
French (16) 16
Polish (14) 14
Italian (12) 12
Chinese (8) 8
Russian (8) 8
Portuguese (7) 7
Czech (6) 6
Korean (6) 6
Hebrew (4) 4
Hungarian (3) 3
Bulgarian (2) 2
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, 04/2015, Volume 2015, Issue 4
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 2000, Volume 162, Issue 6, pp. 2018 - 2020
Journal Article
Journal Article
Free Radical Biology and Medicine, ISSN 0891-5849, 07/2017, Volume 108, pp. S34 - S34
Journal Article
Chemosphere, ISSN 0045-6535, 02/2020, Volume 240, p. 124949
Pharmaceutically active compounds are of great concern due to their detection frequency in the environment and the unexpected risks. In this study, the... 
Removal | Bezafibrate | Algae | Degradation pathways | Pharmaceuticals
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2018, Volume 378, Issue 23, pp. 2171 - 2181
Journal Article
Journal Article
Chemical Engineering Journal, ISSN 1385-8947, 01/2020, Volume 379, p. 122294
Fibrate pharmaceuticals are a group of ubiquitous emerging pollutants, which pose a potential threat to ecosystem and human health. Photocatalysis with... 
g-C3N4 | Active species | Bezafibrate | Photocatalysis
Journal Article
Clinics and Research in Hepatology and Gastroenterology, ISSN 2210-7401, 06/2019, Volume 43, Issue 3, pp. e33 - e36
Journal Article
Psychiatry Research, ISSN 0165-1781, 11/2019, Volume 281, p. 112584
The present study aimed to investigate the effect of bezafibrate on glucolipid abnormalities induced by antipsychotics in schizophrenia. Patients in the... 
Bezafibrate | Glucolipid abnomal prevention | Schizophrenia
Journal Article
Human Molecular Genetics, ISSN 0964-6906, 3/2012, Volume 21, Issue 5, pp. 1124 - 1137
There is substantial evidence that impairment of peroxisome proliferator-activated receptor (PPAR)-γ-coactivator 1α (PGC-1α) levels and activity play an... 
RESPIRATORY-CHAIN | OXIDATIVE STRESS | COACTIVATOR | RECEPTOR-GAMMA | PGC-1-ALPHA | BIOCHEMISTRY & MOLECULAR BIOLOGY | MUTANT HUNTINGTIN | GENETICS & HEREDITY | NULL MICE | NEURODEGENERATION | DYSFUNCTION | ADIPOSE-TISSUE | Neurons - pathology | Vacuoles - ultrastructure | Oxidative Stress | Huntington Disease - pathology | Transcriptional Activation | Bezafibrate - pharmacology | Muscle Fibers, Skeletal - drug effects | Muscle Fibers, Skeletal - metabolism | PPAR gamma - metabolism | Mitochondria - ultrastructure | Gliosis - pathology | Neuroprotective Agents - pharmacology | Muscle Fibers, Skeletal - ultrastructure | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | Adipose Tissue, Brown - ultrastructure | Huntington Disease - drug therapy | Neuroprotective Agents - administration & dosage | Corpus Striatum - pathology | Disease Models, Animal | Mice, Transgenic | Survival Rate | Mitochondria - metabolism | Signal Transduction - genetics | Mitochondria - drug effects | Huntington Disease - metabolism | Bezafibrate - administration & dosage | Phenotype | Animals | Diet | Signal Transduction - drug effects | PPAR gamma - agonists | Huntington Disease - genetics | Mitochondria, Muscle - ultrastructure | Trans-Activators - metabolism | Adipose Tissue, Brown - drug effects | Mice | Mitochondria, Muscle - drug effects | Transcription Factors | Neuroprotection | Animal models | Transgenic mice | Muscles | Lipids | Huntington's disease | Atrophy | Diets | Mitochondria | Gliosis | Bezafibrate | Neostriatum | Glycolysis | Peroxisome proliferator-activated receptors | Adipose tissue (brown) | PGC-1 protein
Journal Article
International Journal of Applied Pharmaceutics, ISSN 0975-7058, 01/2018, Volume 10, Issue 1, pp. 94 - 97
Journal Article
Neurology, ISSN 0028-3878, 02/2014, Volume 82, Issue 7, pp. 607 - 613
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2013, Volume 8, Issue 5, p. e64258
Aim: The aim of the present study was to evaluate whether activation of peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma by Bezafibrate... 
PPAR-ALPHA | INSULIN-RESISTANCE | C57BL/6 MICE | MULTIDISCIPLINARY SCIENCES | LIVER | GENE-EXPRESSION | X-RECEPTOR | HEPATIC STEATOSIS | BEZAFIBRATE | BETA-CELL FUNCTION | ADIPOSE-TISSUE | Prenatal Nutritional Physiological Phenomena | Body Weight | Adipose Tissue, White - metabolism | Diet, High-Fat - adverse effects | Male | Bezafibrate - pharmacology | Adipocytes - physiology | PPAR gamma - metabolism | Female | Drug Evaluation, Preclinical | Sterol Regulatory Element Binding Protein 1 - metabolism | PPAR gamma - genetics | Adipose Tissue, White - pathology | Bezafibrate - therapeutic use | Gene Expression | Pregnancy Complications - etiology | Obesity - complications | Liver - metabolism | Mice, Inbred C57BL | Carbohydrate Metabolism | Cell Size | PPAR alpha - genetics | Prenatal Exposure Delayed Effects - drug therapy | Hypolipidemic Agents - pharmacology | Prenatal Exposure Delayed Effects - etiology | Energy Intake | Fatty Liver - drug therapy | Pregnancy | Animals | Energy Metabolism | Sterol Regulatory Element Binding Protein 1 - genetics | Hypolipidemic Agents - therapeutic use | Mice | PPAR alpha - metabolism | Fatty Liver - etiology | Adipose tissues | Type 2 diabetes | Proteins | Obesity | Diet | Physiological aspects | Triglycerides | Glucose | Dextrose | Carnitine | Adipose tissue | Fat metabolism | Lactation | Weaning | Liver | Body weight | Lipids | Activation | Gestation | Adipocytes | Adiponectin | Mating | Glucose metabolism | Receptors | Alterations | Fatty liver | Rodents | Oxidation | Abnormalities | Mass distribution | Inflammation | Metabolism | Palmitoyltransferase | Carnitine palmitoyltransferase | Glucose tolerance | Progeny | Intolerance | Offspring | Bezafibrate | Body mass | Insulin resistance
Journal Article